Pediatric · PALS

Pediatric tachycardia with a pulse (PALS)

Separate the compensating heart (sinus tachycardia) from the malfunctioning one (SVT, VT); then decide by perfusion between vagal maneuvers and adenosine, and synchronized cardioversion.

Guidelines: AHA 2020 with the 2023 update and confirmed 2025 changes; PALS 2020 with the 2025 pediatric updates

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline. Pediatric content follows the AHA 2020 PALS algorithms with the 2025 AHA/AAP pediatric updates where confirmed.

Walk through it

One step at a time. Each step says what to do and why; at a decision, choose the branch that fits your patient. The map shows where you are.

The interactive walk needs JavaScript. Every step is listed below.

Every step at once
  1. Start

    Tachycardia with a pulse

    • Look at the rate, the QRS width and perfusion.

    Why: Children run fast for many reasons; the algorithm separates the heart compensating (sinus tachycardia) from the heart malfunctioning (SVT, VT).

    Then: Support the ABCs

  2. Do

    Support the ABCs

    • Oxygen as needed; monitor; IV or IO access; 12-lead ECG if it does not delay care.

    Why: Record the rhythm before treatment changes it.

    Then: Is the QRS narrow (0.09 s or less) or wide (more than 0.09 s)?

  3. Decide

    Is the QRS narrow (0.09 s or less) or wide (more than 0.09 s)?

    Why: Children's QRS complexes are narrower than adults', so PALS uses 0.09 seconds as the cut-off.

  4. Decide

    Probable sinus tachycardia or SVT?

    • Sinus: a cause in the history, normal P waves, variable rate; infants usually under 220, children under 180.
    • SVT: abrupt onset, absent or abnormal P waves, fixed rate; infants usually 220 or more, children 180 or more.

    Why: Sinus tachycardia is a response to fever, pain, dehydration or shock: treat the cause. Treating it as SVT removes the compensation.

    Rhythm: AV nodal re-entrant tachycardia (AVNRT)

  5. Then

    Search for and treat the cause

    • Fever, pain, hypovolemia, hypoxia, anemia, shock.

    Why: The rate will settle when the cause is treated.

    Rhythm: Sinus tachycardia

  6. Decide

    Cardiopulmonary compromise?

    Why: Hypotension, altered mental status or signs of shock mean electricity now.

  7. Then

    Vagal maneuvers, then adenosine

    • Infants: ice water to the face (never pressure on the eyes). Children: blowing through a narrow straw, or a modified Valsalva.
    • Adenosine 0.1 mg/kg rapid push (max 6 mg); second dose 0.2 mg/kg (max 12 mg).
    • Expert consultation if it persists.

    Why: Both block the AV node briefly; the re-entry circuit of pediatric SVT almost always runs through it.

    Drugs: Adenosine

  8. Then

    Synchronized cardioversion

    • 0.5–1 J/kg; if not effective, 2 J/kg.
    • Sedate if possible without delaying.
    • Adenosine may be tried first if IV/IO access is already in and it causes no delay.

    Why: A child in shock from SVT needs the rhythm stopped now; synchronization avoids the vulnerable T wave.

    Drugs: Adenosine

  9. Decide

    Possible VT: cardiopulmonary compromise?

    Why: Wide-complex tachycardia in a child is uncommon and should be treated as VT, especially with known heart disease.

    Rhythm: Monomorphic ventricular tachycardia

  10. Then

    Synchronized cardioversion

    • 0.5–1 J/kg, then 2 J/kg.
    • Adenosine only if regular and monomorphic, and only if it does not delay cardioversion.

    Why: Unstable VT with a pulse needs electricity.

  11. Then

    Expert consultation and an antiarrhythmic

    • Adenosine if regular and monomorphic.
    • Amiodarone 5 mg/kg over 20–60 minutes, or procainamide 15 mg/kg over 30–60 minutes; do not routinely give both.
    • Be ready to cardiovert.

    Why: Both drugs can cause hypotension; slow infusion and expert help keep a stable child stable.

    Drugs: Amiodarone, Procainamide

The rhythms

Key points

Telling them apart

  • QRS of 0.09 s or less is narrow in children.
  • SVT: abrupt onset, absent P waves, fixed rate, infants usually ≥220, children ≥180.

Treatment

  • Stable SVT: vagal maneuvers (ice to the face in infants), adenosine 0.1 mg/kg then 0.2 mg/kg.
  • Compromised: synchronized cardioversion 0.5–1 J/kg, then 2 J/kg.

Energies, doses and targets

WhatAs the guideline states itSource
Adenosine IV/IO0.1 mg/kg rapid push (max 6 mg); second dose 0.2 mg/kg (max 12 mg)AHA 2020 PALS tachycardia algorithm
Synchronized cardioversion0.5–1 J/kg; if not effective, 2 J/kgAHA 2020 PALS tachycardia algorithm
Amiodarone IV/IO (wide QRS, with a pulse)5 mg/kg over 20–60 minutesAHA 2020 PALS tachycardia algorithm
Procainamide IV/IO (wide QRS, with a pulse)15 mg/kg over 30–60 minutesAHA 2020 PALS tachycardia algorithm

Mechanisms, cautions and pediatric doses: the drugs. Practise it: megacode cases.

Guidelines and sources

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline.

Algorithms and doses follow the AHA 2020 Guidelines for CPR and ECC, adult algorithms (Part 3: Adult Basic and Advanced Life Support, Circulation 2020;142(suppl 2):S366–S468), checked for changes in:

  • 2023 AHA Focused Update on Adult Advanced Cardiovascular Life Support (Circulation 2024;149:e254–e273)
  • 2025 AHA Guidelines for CPR and ECC, Part 9: Adult Advanced Life Support

Changes in the 2025 guidelines reflected here:

  • Synchronized cardioversion of atrial fibrillation: an initial energy of at least 200 J with a biphasic defibrillator is now recommended, rather than a lower first shock.
  • The tachycardia algorithm refers to the device's recommended energy level rather than listing energies for each rhythm.
  • Intravenous access is preferred to intraosseous access as the first attempt in cardiac arrest.
  • Double sequential defibrillation and vector-change defibrillation for refractory VF remain of uncertain benefit.
  • Sotalol is no longer listed in the tachycardia algorithm; procainamide and amiodarone remain.
  • Routine calcium and sodium bicarbonate are not recommended in cardiac arrest; both are kept for specific causes.
  • After ROSC: titrate oxygen to an SpO₂ of 90–98%, keep the MAP at 65 mm Hg or more, and use deliberate temperature control (32–37.5 °C) for patients not following commands.
  • Polymorphic VT is treated as unstable and defibrillated.

Sources:

  1. Panchal AR, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16 suppl 2):S366–S468.
  2. Perman SM, et al. 2023 American Heart Association Focused Update on Adult Advanced Cardiovascular Life Support. Circulation. 2024;149:e254–e273.
  3. Lavonas EJ, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning. Circulation. 2023;148:e149–e184.
  4. Part 7: Adult Basic Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  5. Part 9: Adult Advanced Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2):S538–S577.
  6. Part 10: Adult and Pediatric Special Circumstances of Resuscitation. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  7. Part 11: Post–Cardiac Arrest Care. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  8. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862.
  9. Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke (AHA/ASA). Stroke. 2026. doi:10.1161/STR.0000000000000513.

The full 2025 guideline text could not be opened when this page was drafted; the 2025 changes listed were confirmed from summaries of AHA's published 2025 algorithms and highlights. Drug doses are the 2020 algorithm doses, which those 2025 algorithms keep. All text and pictures here are original teaching material, not reproductions of AHA algorithms. Education only, not a treatment protocol.